样本编号	SAMC3366693
外部数据库编号	GSA-Human: HRS1048118
样品名称	H9DW0356T
样本标题	Cancer tissue
样品类型	Human sample
物种名称	Homo sapiens
描述信息	We conducted comprehensive omics profiling on 128 GCA patients using mass spectrometry, whole exome sequencing, RNA-Seq, and metabolic assays, and categorized patients into HER2-high, -low, and -negative groups based on HER205 levels.
样本属性	*该样本包含更多受控访问信息，请通过GSA-Human系统申请项目HRA006640数据获取。
发布日期	2026-02-02
项目编号	PRJCA023412
提交者	Li Dong Wang (ldwang2007@126.com)
提交单位	Zhengzhou University
提交日期	2024-02-06

样本包含数据信息

资源名称	描述
GSA-Human (1)	-
HRA006640 (Controlled Access)	Therapeutic targets for gastric cardia adenocarcinoma (GCA) often follow those of gastric cancer, with HER2 being a crucial target. Consequently, therapeutic targets specifically for GCA, particularly for HER2-negative patients, are lacking. Here, we conducted comprehensive omics profiling on 128 GCA patients using mass spectrometry, whole exome sequencing, RNA-Seq, and metabolic assays, and categorized patients into HER2-high, -low, and -negative groups based on HER2 levels. We identified HER2 as a robust prognostic marker for GCA patients, revealing DNA repair pathway enrichment in the HER2-high group and inflammatory features in the low and negative groups. Variations in genome instability were observed across HER2 subgroups, maintaining consistent tumor mutational burden. HER2-negative and low groups exhibited a tumor suppressive immune microenvironment, with an association between HER2 expression and distinct metabolic mechanisms.

资源名称

描述

GSA-Human (1)

HRA006640 (Controlled Access)

Therapeutic targets for gastric cardia adenocarcinoma (GCA) often follow those of gastric cancer, with HER2 being a crucial target. Consequently, therapeutic targets specifically for GCA, particularly for HER2-negative patients, are lacking. Here, we conducted comprehensive omics profiling on 128 GCA patients using mass spectrometry, whole exome sequencing, RNA-Seq, and metabolic assays, and categorized patients into HER2-high, -low, and -negative groups based on HER2 levels. We identified HER2 as a robust prognostic marker for GCA patients, revealing DNA repair pathway enrichment in the HER2-high group and inflammatory features in the low and negative groups. Variations in genome instability were observed across HER2 subgroups, maintaining consistent tumor mutational burden. HER2-negative and low groups exhibited a tumor suppressive immune microenvironment, with an association between HER2 expression and distinct metabolic mechanisms.